All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Drugs for Genetic Disease in Phase II Clinical Development in NETHERLANDS

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Khondrion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases

Lead Product(s): Sonlicromanol

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

The study’s primary objective is to evaluate the dose-effect of Sonlicromanol on the attention domain score of cognitive functioning, Results are expected in the second half of 2020.